Biogen Strikes RNAi Deal with City; Aurion Withdraws IPO

Biogen strikes RNAi deal with City; Aurion withdraws IPO

City will receive $46 million from Biogen under the alliance. Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug.

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to develop select novel RNAi therapies.

RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board

TransCode Therapeutics, a clinical-stage oncology company, has strengthened its scientific leadership by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore, a distinguished researcher in RNA biology and gene silencing mechanisms, brings significant expertise to the company’s innovative cancer therapy programs. As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Dr. Zamore is recognized for his foun…

Biogen and City Therapeutics to partner on RNAi therapies

Biogen and City Therapeutics are set to partner for the development of new RNA interference (RNAi) therapies.

Biogen Commits $46 Million to RNAi Collaboration with City

Biogen has entered into an agreement with City to advan […] The post Biogen Commits $46 Million to RNAi Collaboration with City first appeared on GeneOnline News. The post Biogen Commits $46 Million to RNAi Collaboration with City appeared first on GeneOnline News.

Source: Lenovo Star, Legend Capital WeChat Official Account Hong Kong, May 27, 2025 - (Asia Pacific Business News via SeaPRwire.com) - On May 27, Legend Holdings (3396.HK)'s Legend Capital and Legend Star jointly invested in the innovative chronic disease drug company Page Biopharma (02565.HK), which was successfully listed on the Hong Kong Stock Exchange. During the IPO period, the subscription amount of Paige Biopharmaceuticals' Hong Kong publ…